Abstract
Although Hox genes have been identified as master regulatory genes controlling embryonic development, an alternative view on the role of the Hox gene network suggests that it regulates crucial processes at cellular level in eukaryotic organisms. The Hox network acts at the nuclear cell level as a decoding system for external inductive signals to activate specific genetic programs. Cancer can be considered as an anomalous structure growing inside the human body and following, from an architectural viewpoint, the rules controlling body shape as occurs during embryonic development. As a consequence of this viewpoint, it has been proposed that the whole HOX gene network is involved in controlling phenotype cell identity and three-dimensionality of tissues and organs and, furthermore, that specific HOX genes or groups of genes are implicated in the neoplastic alterations of organs and tissues such as kidney, colon, lung, skin, bladder, breast, prostate. Despite our limited understanding of the mechanisms involved, it has already been possible to identify the specific HOX genes perturbed in certain types of human cancers with greater benefit for cancer patients than for better known oncogenes. Here we foresee the start of clinical trials with the purpose of targeting specific HOX genes in order to achieve a therapeutic effect in cancer patients.
Keywords: Tritorax genes, Antisense oligonucleotides, Kidney Cancer, Breast Cancer, RNA interference (RNAi)
Current Cancer Therapy Reviews
Title: The HOX Gene Network as a Potential Target for Cancer Therapy
Volume: 3 Issue: 1
Author(s): Monica Cantile, Giulia Schiavo, Luigi Terracciano and Clemente Cillo
Affiliation:
Keywords: Tritorax genes, Antisense oligonucleotides, Kidney Cancer, Breast Cancer, RNA interference (RNAi)
Abstract: Although Hox genes have been identified as master regulatory genes controlling embryonic development, an alternative view on the role of the Hox gene network suggests that it regulates crucial processes at cellular level in eukaryotic organisms. The Hox network acts at the nuclear cell level as a decoding system for external inductive signals to activate specific genetic programs. Cancer can be considered as an anomalous structure growing inside the human body and following, from an architectural viewpoint, the rules controlling body shape as occurs during embryonic development. As a consequence of this viewpoint, it has been proposed that the whole HOX gene network is involved in controlling phenotype cell identity and three-dimensionality of tissues and organs and, furthermore, that specific HOX genes or groups of genes are implicated in the neoplastic alterations of organs and tissues such as kidney, colon, lung, skin, bladder, breast, prostate. Despite our limited understanding of the mechanisms involved, it has already been possible to identify the specific HOX genes perturbed in certain types of human cancers with greater benefit for cancer patients than for better known oncogenes. Here we foresee the start of clinical trials with the purpose of targeting specific HOX genes in order to achieve a therapeutic effect in cancer patients.
Export Options
About this article
Cite this article as:
Cantile Monica, Schiavo Giulia, Terracciano Luigi and Cillo Clemente, The HOX Gene Network as a Potential Target for Cancer Therapy, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126593
DOI https://dx.doi.org/10.2174/157339407780126593 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer
Current Cancer Drug Targets Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Endoscopic Microscopy Using Optical Coherence Tomography
Current Medical Imaging Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Marine Sponges: Potential Sources of New Antimicrobial Drugs
Current Pharmaceutical Biotechnology Integrative System Biology Strategies for Disease Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Genetics of Bladder Malignant Tumors in Childhood
Current Genomics A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry The Proteolytic Systems of Muscle Wasting
Recent Advances in DNA & Gene Sequences (Discontinued) Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Drug-Metabolizing Enzymes Mechanisms and Functions
Current Drug Metabolism Subject Index to Volume 9
Current Pharmaceutical Design Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Physical and Chemical Stimuli-Responsive Drug Delivery Systems: Targeted Delivery and Main Routes of Administration
Current Pharmaceutical Design Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics